Mural Oncology plc (MURA NASDAQ) stock market data APIs
$2.0797
0.01(0.5%)
as of September 17, 2025
Try our APIs with
free plan!
Mural Oncology plc Financial Data Overview
Price chart is built with
Anychart
Mural Oncology plc operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.
Prev. Close
2.0797
Open
2.0894
High
2.0797
Low
2.0894
52 wk Range
0.95-4.74
Market Cap
35 862 K
Shares Outstanding
17 325 K
EPS
-2.78
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Mural Oncology plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Mural Oncology plc data using free add-ons & libraries
Get Mural Oncology plc Fundamental Data
Mural Oncology plc Fundamental data includes:
- Net Revenue:
- EBITDA: -131 934 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-04
- EPS/Forecast: -1.1
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Mural Oncology plc News
New
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, GES, MURA, TZUP on Behalf of Shareholders
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or br...
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger – NWE, GES, MURA, and TZUP
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for sharehold...
Citadel Group discloses 1.61% stake in Mural Oncology
DUBLIN - Investment firm Citadel Group has disclosed a 1.61% stake in Mural Oncology plc, according to a regulatory filing published Tuesday. The disclosure, made under Irish Takeover Panel rules, sh...
Citadel Group discloses 2.81% stake in Mural Oncology
DUBLIN - Investment firm Citadel Group has disclosed a 2.81% stake in Mural Oncology plc, according to a regulatory filing published Thursday. The disclosure, made under Irish Takeover Panel rules, s...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
